Biocure Technology Inc.
CUREX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.99% | 60.94% | 59.50% | 52.33% | 161.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.99% | 60.94% | 59.50% | 52.33% | 123.80% |
| Operating Income | -55.99% | -60.94% | -59.50% | -52.33% | -123.80% |
| Income Before Tax | -263.78% | -268.24% | -259.39% | -244.11% | -4.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -263.78% | -268.24% | -259.39% | -244.11% | -4.21% |
| Earnings from Discontinued Operations | 95.70% | 96.53% | 91.23% | 69.62% | -38.52% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -91.86% | -94.70% | -79.48% | -59.76% | 117.34% |
| Net Income | -346.70% | -385.29% | -0.27% | -18.52% | -34.97% |
| EBIT | -55.99% | -60.94% | -59.50% | -52.33% | -123.80% |
| EBITDA | -- | -- | -- | -- | -115.33% |
| EPS Basic | -373.71% | -421.76% | -66.67% | -82.88% | -22.20% |
| Normalized Basic EPS | -124.51% | -99.57% | -121.68% | -116.03% | -124.20% |
| EPS Diluted | -373.71% | -421.76% | -66.67% | -82.88% | -22.20% |
| Normalized Diluted EPS | -124.51% | -99.57% | -121.68% | -116.03% | -124.20% |
| Average Basic Shares Outstanding | -12.59% | 153.34% | 153.65% | 158.77% | 167.92% |
| Average Diluted Shares Outstanding | -12.59% | 153.34% | 153.65% | 158.77% | 167.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |